![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/04/2892718/0/en/BioVersys-Awarded-Non-Dilutive-Funding-From-CF-AMR-Syndicate-Collaborative-Discovery-Programme.html
https://www.globenewswire.com/news-release/2024/05/07/2876301/0/en/BioVersys-Announces-Expansion-of-Strategic-Collaboration-With-GSK-and-Extension-of-Its-Series-C-Round-by-CHF-12-3-Million.html
https://www.globenewswire.com/news-release/2022/10/25/2540712/35690/en/OpGen-Subsidiary-Curetis-and-BioVersys-Sign-Collaboration-Agreement-for-Clinical-Trial-Support.html
https://www.contractpharma.com/contents/view_breaking-news/2021-04-14/bioversys-gets-eib-funds-to-address-antimicrobial-resistance/?widget=listSection
https://www.biospectrumasia.com/news/25/17145/bioversys-announces-first-subjects-dosed-in-ph-1-clinical-trial-of-bv100.html
https://www.b3cnewswire.com/202011182151/bioversys-announces-first-subjects-dosed-in-phase-1-clinical-trial-of-bv100.html
https://www.pharmiweb.com/press-release/2020-09-01/bioversys-announces-chf-19-million-financing-to-advance-novel-amr-candidates-into-clinical-development#:~:text=BASEL%2C%20Switzerland%2C%20September%2001%2C,the%20appointment%20of%20Dr.%20Eduard